MainLine NSE • BSE Financial Services

Paras Healthcare Ltd IPO

Tech-led NBFC delivering AI/ML driven retail credit across Tier-2 & Tier-3 India.

Live Now
Price Band ₹660 – ₹693 per share per share
Lot Size 21 Shares
Min. Investment ₹14553
Issue Size ₹1450 Cr
Face Value ₹1
IPO Open 21 October 2026
IPO Close 23 October 2026
Allotment 26 Oct 2026
Listing 28 Oct 2026
Live demand

Subscription status for Paras Healthcare Ltd IPO

As of 21 Oct 26, 9:40 PM. Will get Updated in every 30 minutes

QIB 0.00x

Qualified Institutional Buyers

NII 0.06x

Non-Institutional Investors

Retail 0.61x

Retail Individual Investors

Total 0.13x

Across all investor categories

Key dates

IPO schedule for Paras Healthcare Ltd

From the day bidding opens to listing — every milestone you need to track.

IPO Open 21 Oct 2026
IPO Close 23 Oct 2026
Allotment 26 Oct 2026
Refund / Unblock 27 Oct 2026
Listing 28 Oct 2026
About the company

Who is Paras Healthcare Ltd ?

Paras Healthcare Limited was incorporated as Arbian Frozen Foods Private Limited', a Private Limited Company, pursuant to a Certificate of Incorporation dated December 21, 1987, issued by the RoC. Company became a deemed public company with effect from July 1, 1993, and the name was changed to 'Arbian Frozen Foods Limited'. Company was re-converted from a deemed public company to a Private Limited Company and the name of Company was changed to Arbian Frozen Foods Private Limited' and the Certificate of Incorporation was endorsed by the RoC on June 16, 2003. Subsequently, Company name was changed from Arbian Frozen Foods Private Limited' to Paras Healthcare Private Limited' by the RoC on July 21, 2003. Company was converted from a Private Company to a Public Company, and name was changed to 'Paras Healthcare Limited', vide fresh Certificate of Incorporation on July 18, 2024.

The Company has eight hospitals that it operate under the 'Paras Health' brand, which are spread across five states and one union territory in North India - Gurugram and Panchkula in Haryana; Patna and Darbhanga in Bihar; Kanpur, Uttar Pradesh; Udaipur, Rajasthan; Ranchi, Jharkhand; and Srinagar in the Union Territory of Jammu and Kashmir.

The Company established first hospital in Gurugram, Haryana in 2006 with 200 beds to provide affordable, accessible and quality healthcare services in North India and serve patients with compassion. Since then, it set up hospitals and focused on ramping up the operations. The hospital in Gurugram was the first corporate hospital entrant among the Peers in 2006 in the city and hospital in Srinagar is the largest private hospital in the city in terms of bed capacity with 200 beds.

In July 2017, Commelina Ltd (an affiliate of Creador, global private equity firm) acquired a stake in the Company. In October 2022, the Company acquired Plus Medicare Hospitals Private Limited at Udaipur. Thereafter, the Company commenced operations at Srinagar hospital in 2023 with 200 bed capacity and at Kanpur in 2024 with 435 bed capacity. The Company increased bed capacity from 1,250 beds as of March 31, 2022 to 2,135 beds as of March 31, 2024.

The Company' offer several clinical specialties across the hospitals including cardiac sciences, oncology, neurosciences, gastrosciences and orthopedics and joint replacement. It has established centres of excellence across the hospitals, where the Company provide clinical specialties and these centres have been instrumental in launching new programs including organ transplant programs.

Financial track record

Financials at a glance

Three-year trajectory of revenue, profit and assets — restated as per the RHP.

Revenue PAT Total Assets
FY 2026
FY 2025
FY 2024
Metric (₹ Cr)FY 2026FY 2025FY 2024
Total Income1,416.481,175.371,045.20
EBITDA334.11185.16190.00
PAT92.753.2269.08
AUM2,110.221,788.221,405.78

Strengths & Risks

A balanced look at what works in the company's favour and what investors should watch.

Strengths

  • One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First Mover Advantage and a Well-Recognized Brand.
  • Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties.
  • Capital-Efficient and Flexible Operating Model with Disciplined Expansion.
  • Delivering High-Quality Clinical Care Through Renowned Clinicians, Supported with Modern Equipment.
  • Digital Technology Enabling Clinical Effectiveness, Patient Experience and Operational Efficiencies.
  • Doctor-Led Professional Management Team with Proven Execution Capabilities.

Risks

  • The Company has incurred losses during the three months period ended June 30, 2025 and Fiscals 2025 and 2024 of Rs. (10.24) million, Rs. (579.83) million and Rs. (153.31) million, respectively, on a consolidated basis. While the company were profitable in the three months period ended June 30, 2026 and Fiscal 2026, its cannot assure you that the company will continue to remain profitable in the future.
  • The company's Subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited have collectively incurred a loss of Rs. (203.82) million, Rs. (520.89) million, Rs. (822.38) million and Rs. (872.69) million during the three months period ended June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. Its cannot assure you that these Subsidiaries will turn profitable in the future.
  • The company is highly dependent on doctors, nurses, other healthcare professionals and housekeeping and support staff for its operations. The company has experienced high attrition rates of 12.01%, 16.09%, 60.38%, 66.74% and 65.27% in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If the company is unable to reduce or manage the attrition rates of these professionals, its business, results of operations and financial condition may be adversely affected.
  • Five of the company's eight hospitals are located in North India. In the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, the revenue from these hospitals accounted for 68.07%, 66.89%, 66.07%, 68.40% and 67.33% of its revenue from operations, respectively. Any adverse developments affecting these hospitals or the regions in which they are located could affect the company's business, results of operations and financial condition.
  • The name of one of the members of our Promoter Group, Harbaksh Singh Khangura appears in the CIBIL wilful defaulter database, and there is no guarantee that his name will be removed from the CIBIL defaulter database or that he will not be subject to any adverse proceedings or rulings in the future.
  • We generate a significant portion of our revenue from the provision of cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports injury and renal sciences (collectively, "CONGOR") specialties, which contributed 74.35%, 75.30%, 74.70%, 71.92% and 72.34% of our revenue from operations in the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, respectively. Any adverse developments in the demand for such services could adversely affect our business, results of operations and financial condition.
  • The provision of healthcare services involves high costs such as employee benefit expenses, retainers and consultants fee and purchases of stock-in-trade, which together accounted for 66.13%, 64.40%, 65.08%, 63.69% and 66.95% of our total expenses in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If we fail to pass on these costs to patients, our business, results of operations and financial condition could be adversely affected.
  • We conduct the operations of six of our eight hospitals on leased premises. We operate certain hospitals through revenue share arrangements and long-term leases, and we operate one hospital pursuant to a public-private partnership arrangement. Any adverse developments in our relationships with our lessors or counterparties, or our inability to renew such arrangements, could adversely affect our business, financial condition and results of operations.
  • We have certain contingent liabilities that have been disclosed in our financial statements, which if they materialize, may adversely affect our results of operations, cash flows and financial condition. Our contingent liabilities, as of June 30, 2026, constituted 89.55% of our net worth.
  • There are outstanding litigations against our Company, Subsidiaries, Promoter, Directors, Key Managerial Personnel and Senior Management, and there were certain regulatory and statutory proceedings initiated against our Promoter and Directors in the past. Any adverse decision in such proceedings, or similar instances in the future may render us or them liable for penalties, and may adversely affect our business, cash flows and reputation.

Paras Healthcare Ltd IPO — frequently asked questions

The Paras Healthcare Ltd IPO opens on 21 October 2026 and closes on 23 October 2026. Bidding is accepted from 10:00 AM on the open date until 5:00 PM on the close date. The IPO is available to all eligible investors including retail individual investors, non-institutional investors, and qualified institutional buyers.
The price band for Paras Healthcare Ltd IPO is Rs 660 to Rs 693 per share. The lot size is 21 shares per lot, requiring a minimum investment of Rs 14553 at the upper price band. Investors must apply for a minimum of one lot and can apply for up to 21 lots as per SEBI guidelines.
You can apply for the Paras Healthcare Ltd IPO through the Chola Securities app or web platform using UPI or ASBA. Log in to your account, navigate to the IPO section, select Paras Healthcare Ltd from the open IPOs list, enter your bid quantity and price within the price band, and submit your application. You need an active demat account, a linked bank account, and a valid PAN to apply. Bidding closes on 23 October 2026 at 5:00 PM.
Allotment for Paras Healthcare Ltd IPO is scheduled on 26 Oct 2026. Refunds or unblocking of funds for unsuccessful applicants will be processed on 27 Oct 2026. The shares are expected to list on 28 Oct 2026. You can check your allotment status on the Chola Securities IPO page or through the registrar's website using your PAN.
Chola Securities' research team has reviewed the Paras Healthcare Ltd IPO based on the company's financials, business model, valuation, and sector outlook. The recommendation is available on this page. Investors are advised to read the full IPO note along with the company's Red Herring Prospectus before making an investment decision.
Yes, you can revise or withdraw your Paras Healthcare Ltd IPO bid before the subscription window closes on 23 October 2026 at 5:00 PM. Revisions can include changing the quantity or price within the allowed price band. To withdraw, cancel your application through the platform before the closing time. Once the subscription period ends, no further changes are permitted.
Ready to invest

Apply for the Paras Healthcare Ltd through the Chola Securities Mobile & Web App

Bidding closes 09 May 2026 — apply via UPI in under 60 seconds and skip the paperwork.

Chola Securities mobile and web app preview